Skip to main content
SpringerLink
Log in
Book cover

Antiepileptic Drug Interactions pp 51–54Cite as

Lacosamide

  • Chapter
  • First Online:

  • 1099 Accesses

Abstract

The pharmacokinetic characteristics of lacosamide are described and the interaction effects of concomitant antiepileptic drugs on lacosamide in terms of its pharmacokinetics and pharmacodynamics are highlighted.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Summary of Product Characteristics: Brivaracetam (Briviact). UCB Pharma Ltd. Last update 21 Jan 2016.

    Google Scholar 

  2. Markoula S, Teotonio R, Ratnaraj N, Duncan JS, Sander JW, Patsalos PN. Lacosamide serum concentrations in adult patients with epilepsy: the influence of gender, age, dose, and concomitant antiepileptic drugs. Ther Drug Monit. 2014;36:494–8.

    Article  CAS  PubMed  Google Scholar 

  3. Contin M, Albani F, Riva R, Candela C, Mohamed S, Baruzzi A. Lacosamide therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs. Ther Drug Monit. 2013;35:849–52.

    Article  CAS  PubMed  Google Scholar 

  4. Novy J, Patsalos PN, Sander JW, Sisodiya SM. Lacosamide neurotoxicity associated with concomitant use of sodium-blocking antiepileptic drugs: a pharmacodynamic interaction? Epilepsy Behav. 2011;20:20–3.

    Article  PubMed  Google Scholar 

  5. Thomas D, Scharfenecker U, Schiltmeyer B, Doty P, Cawello W, Horstmann R. Low potential for drug-drug interactions of lacosamide. Epilepsia. 2006;47(Suppl 4):200.

    Google Scholar 

  6. Nickel B, Zisowsky J, Cawello W, Lovern M, Sargentini-Maier ML. Population pharmacokinetics of LCM in subjects with partialonset seizures: results from two phase III trials. J Clin Pharmacol. 2008;48:1129.

    Google Scholar 

  7. Cawello W, Bonn R. No pharmacokinetic interaction between lacosamide and valproic acid in healthy volunteers. J Clin Pharmacol. 2012;52:1739–48.

    Article  CAS  PubMed  Google Scholar 

  8. Jones GL, Popli GS, Silvia MT. Lacosamide-induced valproic acid toxicity. Pediatr Neurol. 2013;48:308–10.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Therapeutic Drug Monitoring Unit Department of Clinical and Experimental Epilepsy, UCL-Institute of Neurology, Queen Square, London, UK

    Philip N. Patsalos

  2. Chalfont Centre for Epilepsy Chalfont St Peter, Buckinghamshire, UK

    Philip N. Patsalos

Authors
  1. Philip N. Patsalos
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Patsalos, P.N. (2016). Lacosamide. In: Antiepileptic Drug Interactions. Springer, Cham. https://doi.org/10.1007/978-3-319-32909-3_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-32909-3_10

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-32908-6

  • Online ISBN: 978-3-319-32909-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation